Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esaxerenone versus trichlormethiazide in essential hypertension inadequately controlled on ARB or CCB
jRCTs031220372Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in essential hypertension comparing Esaxerenone add-on arm with Trichlormethiazide add-on arm (2 arms). Primary endpoints: Change from baseline in morning home systolic blood pressure and Change from baseline in morning home diastolic blood pressure. Started Dec 2022; status: completed.
02
Drugs
esaxerenoneTrichlormethiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCTs031220372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220372.